Few patients with migraine receive or are offered preventive therapy, leaving a significant treatment gap in this patient population, new research suggests. Investigators found that among patients with migraine who are eligible for preventive therapy, more than a third were…

Atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that’s been in development as a preventive treatment for chronic migraine, has been found to have fewer side effects and similar hepatic function profile to standard of care oral treatment after…